STOCK TITAN
  1. Home
  2. News
  3. MBIO

Mustang Bio Inc - MBIO STOCK NEWS

Welcome to our dedicated news page for Mustang Bio (Ticker: MBIO), a resource for investors and traders seeking the latest updates and insights on Mustang Bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Mustang Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Mustang Bio's position in the market.

News
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
Rhea-AI Summary
Mustang Bio, Inc. announces expansion into autoimmune diseases with MB-106, a CD20-targeted CAR T-cell therapy. The company plans to conduct a Phase 1 clinical trial for autoimmune diseases and a pivotal trial for Waldenstrom macroglobulinemia. MB-106 has shown promising results in B-cell non-Hodgkin lymphoma, indicating potential for broader applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.64%
Tags
none
-
News
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Rhea-AI Summary
Mustang Bio, Inc. announces financial results and corporate highlights for 2023, including positive data from clinical trials for MB-106 and plans for a registrational CAR-T trial for Waldenstrom macroglobulinemia. Despite a decrease in cash, the company remains focused on development programs and strategic partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.62%
Tags
earnings
-
News
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
Rhea-AI Summary
Mustang Bio, Inc. announced Phase 1 clinical data published in Nature Medicine showing promising safety and clinical activity of MB-101 CAR T-cell therapy for recurrent malignant glioma, including glioblastoma. Patients achieved stable disease or better in 50%, with two partial responses and two complete responses. The therapy exhibited a 70% improvement in median overall survival compared to expected rates, with well-tolerated delivery methods and manageable adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.3%
Tags
clinical trial
News
City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial
Rhea-AI Summary
A Phase 1 CAR T cell therapy trial at City of Hope for glioblastoma shows promising results. The trial, the largest reported for solid tumors, used CAR T cells targeting IL13Rα2. Half of the patients had stable disease for at least two months, with two partial responses and two complete responses. The therapy was well-tolerated, with a median overall survival of eight months. Patients receiving optimized doses had a median survival of 10.2 months, surpassing the expected rate for recurrent glioblastoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.55%
Tags
clinical trial
-
News
Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
Rhea-AI Summary
Mustang Bio, Inc. (MBIO) announced that Manuel Litchman, M.D., President and CEO, will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference on January 18, 2024, at 4:30 p.m. EST, focusing on the translation of medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.82%
Tags
conferences
-
News
Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting
Rhea-AI Summary
Mustang Bio, Inc. (MBIO) announces updated encouraging safety and efficacy data from its multicenter Phase 1/2 clinical trial of MB-106, a CD20-targeted, 3rd-generation autologous CAR T-cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. The data showed favorable safety profile, complete response rate, and durability in treatment, with 100% of patients with follicular lymphoma achieving a complete response. Outpatient administration was found to be feasible, and MB-106 has a tolerable safety profile with no occurrence of CRS above grade 1 and no ICANS of any grade.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
clinical trial
News
Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
Rhea-AI Summary
Mustang Bio, Inc. (MBIO) announced Q3 2023 financial results, including $10.3 million in cash, and recent corporate highlights. MB-106, a CD20-targeted CAR-T cell therapy, showed promising safety and efficacy results in treating B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. The FDA accepted the IND application for MB-109, a combination therapy for recurrent glioblastoma and high-grade astrocytoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.89%
Tags
earnings
-
News
Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting
Rhea-AI Summary
Mustang Bio announces positive interim data from Phase 1/2 clinical trial of MB-106, a CAR-T cell therapy for lymphoma patients. Four patients achieved complete response or very good partial response. Safety profile is favorable with no dose-limiting toxicities observed. CAR-T cell persistence is ongoing at 6 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.91%
Tags
none
-
News
Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
Mustang Bio, Inc. has closed its registered direct offering, raising approximately $4.4 million in gross proceeds. The offering consisted of 2,588,236 shares of common stock at a purchase price of $1.70 per share. In addition, Mustang issued unregistered warrants to purchase up to 2,588,236 shares of common stock at an exercise price of $1.58 per share. The net proceeds will be used for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
offering
News
Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
Mustang Bio, Inc. has entered into a definitive agreement for the issuance and sale of 2,588,236 shares of common stock in a registered direct offering priced at $1.70 per share. The company will also issue unregistered warrants to purchase up to 2,588,236 shares of common stock. The offering is expected to close on October 30, 2023, with gross proceeds of approximately $4.4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.19%
Tags
offering
Stock MBIO logo
Mustang Bio Inc

Nasdaq:MBIO

MBIO Rankings

N/A Ranked by Market Cap
#5340 Ranked by Stock Gains
N/A Ranked by Dividends

MBIO Stock Data

5.28M
6.43M
22.77%
11.11%
1.71%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About MBIO

mustang bio, inc., a subsidiary of fortress biotech, inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient’s own immune system to eliminate cancer cells. mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. mustang has partnered with the city of hope national medical center (“coh”) and fred hutchinson cancer research center in the development of proprietary chimeric antigen receptor (car) engineered t cell (car t) therapies across many cancers. mustang’s lead programs are in phase 1 clinical trials at coh: mb-101 for the treatment of brain cancer and mb-102 as a therapeutic agent in acute myeloid leukemia.